

					n 50% below the cutoff and the cutoff)	and 50% above the cutoff)	the cutoff)	
AM P	Viewer A	+	0	0	1	11	29	100% (84.5% - 100%)
		-	10	18	11	0	0	97.5% (82% - 100%)
Viewer B	+	0	0	2	11	29	100% (84.5% - 100%)	
	-	10	18	10	0	0	95% (79.5% - 100%)	
Viewer C	+	0	0	2	11	29	100% (84.5% - 100%)	
	-	10	18	10	0	0	95% (79.5% - 100%)	
BA R	Viewer A	+	0	0	2	20	20	100% (84.5% - 100%)
		-	10	10	18	0	0	95% (79.5% - 100%)
Viewer B	+	0	0	2	20	20	100% (84.5% - 100%)	
	-	10	10	18	0	0	95% (79.5% - 100%)	
Viewer C	+	0	0	2	20	20	100% (84.5% - 100%)	
	-	10	10	18	0	0	95% (79.5% - 100%)	
BU P	Viewer A	+	0	0	1	16	24	100% (84.5% - 100%)
		-	10	18	11	0	0	97.5% (82% - 100%)
Viewer B	+	0	0	1	16	24	100% (84.5% - 100%)	
	-	10	18	11	0	0	97.5% (82% - 100%)	
Viewer C	+	0	0	2	16	24	100% (84.5% - 100%)	
	-	10	18	10	0	0	95% (79.5% - 100%)	
BZ O	Viewer A	+	0	0	2	20	20	100% (84.5% - 100%)
		-	10	10	18	0	0	95% (79.5% - 100%)
Viewer B	+	0	0	2	20	20	100% (84.5% - 100%)	
	-	10	10	18	0	0	95% (79.5% - 100%)	
Viewer C	+	0	0	2	20	20	100% (84.5% - 100%)	
	-	10	10	18	0	0	95% (79.5% - 100%)	
CO C	Viewer A	+	0	0	2	11	29	100% (84.5% - 100%)
		-	10	10	18	0	0	95% (79.5% - 100%)
Viewer B	+	0	0	1	11	29	100% (84.5% - 100%)	
	-	10	10	19	0	0	97.5% (82% - 100%)	
Viewer C	+	0	0	2	11	29	100% (84.5% - 100%)	
	-	10	10	18	0	0	95% (79.5% - 100%)	
EtG	Viewer A	+	0	0	0	17	21	95% (79.5% - 100%)
		-	10	12	18	2	0	100% (84.5% - 100%)
Viewer B	+	0	0	0	18	21	97.5% (82% - 100%)	
	-	10	12	18	1	0	100% (84.5% - 100%)	
Viewer C	+	0	0	0	18	21	97.5% (82% - 100%)	
	-	10	12	18	1	0	100% (84.5% - 100%)	
FTY	Viewer A	+	0	0	1	18	22	100% (84.5% - 100%)
		-	10	12	17	0	0	97.5% (82% - 100%)
Viewer B	+	0	0	1	18	22	100% (84.5% - 100%)	
	-	10	12	17	0	0	97.5% (82% - 100%)	
Viewer C	+	0	0	1	18	22	100% (84.5% - 100%)	
	-	10	12	17	0	0	97.5% (82% - 100%)	
K2	Viewer A	+	0	0	1	18	22	100% (84.5% - 100%)
		-	10	12	17	0	0	97.5% (82% - 100%)
Viewer B	+	0	0	0	17	22	97.5% (82% - 100%)	
	-	10	12	18	1	0	100% (84.5% - 100%)	
Viewer C	+	0	0	0	15	22	92.5% (77% - 100%)	
	-	10	12	18	3	0	100% (84.5% - 100%)	
KR A	Viewer A	+	0	0	2	20	20	100% (84.5% - 100%)
		-	10	10	18	0	0	95% (79.5% - 100%)
Viewer B	+	0	0	1	20	20	100% (84.5% - 100%)	
	-	10	10	19	0	0	97.5% (79.5% - 100%)	
Viewer C	+	0	0	2	20	20	100% (84.5% - 100%)	
	-	10	10	18	0	0	95% (79.5% - 100%)	
MD MA	Viewer A	+	0	0	2	20	20	100% (84.5% - 100%)
		-	10	10	18	0	0	95% (79.5% - 100%)
Viewer B	+	0	0	2	20	20	100% (84.5% - 100%)	
	-	10	10	18	0	0	95% (79.5% - 100%)	
Viewer C	+	0	0	2	20	20	100% (84.5% - 100%)	
	-	10	10	18	0	0	95% (79.5% - 100%)	
ME T (m AMP)	Viewer A	+	0	0	1	20	20	100% (84.5% - 100%)
		-	10	16	13	0	0	97.5% (82% - 100%)
Viewer B	+	0	0	2	20	20	100% (84.5% - 100%)	
	-	10	16	12	0	0	95% (79.5% - 100%)	
Viewer C	+	0	0	2	20	20	100% (84.5% - 100%)	
	-	10	16	12	0	0	95% (79.5% - 100%)	
MO P/ OPI	Viewer A	+	0	0	2	20	20	100% (84.5% - 100%)
		-	10	19	9	0	0	95% (79.5% - 100%)
Viewer B	+	0	0	2	20	20	100% (84.5% - 100%)	
	-	10	19	9	0	0	95% (79.5% - 100%)	
Viewer C	+	0	0	1	20	20	100% (84.5% - 100%)	
	-	10	19	10	0	0	97.5% (82% - 100%)	
MT D	Viewer A	+	0	0	1	19	21	100% (84.5% - 100%)
		-	10	12	17	0	0	97.5% (82% - 100%)
Viewer B	+	0	0	2	19	21	100% (84.5% - 100%)	
	-	10	12	16	0	0	95% (79.5% - 100%)	
Viewer C	+	0	0	1	19	21	100% (84.5% - 100%)	
	-	10	12	17	0	0	97.5% (82% - 100%)	
OX Y	Viewer A	+	0	0	1	19	21	100% (84.5% - 100%)
		-	10	20	9	0	0	97.5% (82% - 100%)
Viewer B	+	0	0	1	19	21	100% (84.5% - 100%)	
	-	10	20	9	0	0	97.5% (82% - 100%)	
Viewer C	+	0	0	1	19	21	100% (84.5% - 100%)	
	-	10	20	9	0	0	97.5% (82% - 100%)	
PC P	Viewer A	+	0	0	1	18	22	100% (84.5% - 100%)
		-	10	13	16	0	0	97.5% (82% - 100%)
Viewer B	+	0	0	2	18	22	100% (84.5% - 100%)	
	-	10	13	15	0	0	95% (79.5% - 100%)	
Viewer C	+	0	0	1	18	22	100% (84.5% - 100%)	
	-	10	13	16	0	0	97.5% (82% - 100%)	
TH C	Viewer A	+	0	0	1	18	22	100% (84.5% - 100%)
		-	10	12	17	0	0	97.5% (82% - 100%)
Viewer B	+	0	0	1	18	22	100% (84.5% - 100%)	
	-	10	12	17	0	0	97.5% (82% - 100%)	
Viewer C	+	0	0	1	18	22	100% (84.5% - 100%)	
	-	10	12	17	0	0	97.5% (82% - 100%)	
TR A	Viewer A	+	0	0	2	19	21	100% (84.5% - 100%)
		-	10	20	8	0	0	95% (79.5% - 100%)

Viewer	+	0	0	2	19	21	100% (84.5% - 100%)
B	-	10	20	8	0	0	95% (79.5% - 100%)
C	+	0	0	1	19	21	100% (84.5% - 100%)
	-	10	20	9	0	0	97.5% (82% - 100%)

Precision and Sensitivity

To investigate the precision and sensitivity, each drug sample was analyzed at the following concentrations: cutoff -100%, cutoff -75%, cutoff -50%, cutoff -25%, cutoff, cutoff +25%, cutoff +50%, cutoff +75% and the cutoff +100%. All concentrations were confirmed with GC-MS. The study was performed 2 runs /day and lasted 25 days using three different lots of the corresponding drug test. Totally 3 operators participated in the study of the corresponding drug test. Each of the 3 operators tests 2 aliquots at each concentration for each lot per day (2 runs/day), for a total of 50 determinations per concentration per lot of the corresponding drug test.

Drug Test	Approximate Concentration of Sample (ng/mL)	Number of Determinations per Lot	Results Negative/Positive			
			Lot 1	Lot 2	Lot 3	
AMP	0	50	50/0	50/0	50/0	
	250	50	50/0	50/0	50/0	
	500	50	50/0	50/0	50/0	
	750	50	50/0	50/0	50/0	
	1000	50	5/45	6/44	6/44	
	1250	50	0/50	0/50	0/50	
	1500	50	0/50	0/50	0/50	
	1750	50	0/50	0/50	0/50	
	2000	50	0/50	0/50	0/50	
	BAR	0	50	50/0	50/0	50/0
		75	50	50/0	50/0	50/0
		150	50	50/0	50/0	50/0
		225	50	50/0	50/0	50/0
		300	50	5/45	5/45	6/44
		375	50	0/50	0/50	0/50
450		50	0/50	0/50	0/50	
525		50	0/50	0/50	0/50	
600		50	0/50	0/50	0/50	
BUP		0	50	50/0	50/0	50/0
		2.5	50	50/0	50/0	50/0
		5.0	50	50/0	50/0	50/0
		7.5	50	50/0	50/0	50/0
		10.0	50	5/45	5/45	6/44
		12.5	50	0/50	0/50	0/50
	15.0	50	0/50	0/50	0/50	
	17.5	50	0/50	0/50	0/50	
	20.0	50	0/50	0/50	0/50	
	BZO	0	50	50/0	50/0	50/0
		75	50	50/0	50/0	50/0
		150	50	50/0		

Cortisone	Tetrahydrozoline	Venlafaxine HCl
Deoxycorticosterone	Thiamine	Verapamil
Dextromethorphan	Thioridazine	Sertraline
Diclofenac	Diphenhydramine	Zomepirac
Diflunisal	D,L-Octopamine	

ASSISTANCE

If you have any question regarding to the use of this product, please call our Toll Free Number 1-888-444-3657(9:30 a.m. to 5:00 p.m. CDT M-F).

BIBLIOGRAPHY OF SUGGESTED READING

Baselt, R.C. Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications, Davis, CA, 1982.
 Ellenhorn, M.J. and Barceloux, D. G Medical Toxicology. Elsevier Science Publishing Company, Inc., New York, 1988
 Gilman, A. G., and Goodman, L. S. The Pharmacological Fluids, in Martin WR(ed): Drug Addiction I, New York, Spring – Verlag, 1977.
 Harvey, R.A., Champe, P.C. Lippincotts Illustrated Reviews. Pharmacology. 91-95, 1992.
 Hawks RL, CN Chiang. Urine Testing for drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monography 73, 1986
 Hofmann F.E., A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects, New York, Oxford University Press, 1983.
 McBay, A. J. Drug-analysis technology--pitfalls and problems of drug testing. Clin. Chem. 33,33B-40B, 1987.

ADDITIONAL INFORMATION AND RESOURCES

The following list of organizations may be helpful to you for counseling support and resources. These groups also have an Internet address which can be accessed for additional information.
 National Clearinghouse for Alcohol and Drug Information www.health.org 1-800-729-6686
 Center for Substance Abuse Treatment www.health.org 1-800-662-HELP
 The National Council on Alcoholism and Drug Dependence www.ncadd.org 1-800-NCA-CALL
 American Council for Drug Education (ACDE) www.acde.org 1-800-488-DRUG

INDEX OF SYMBOLS



Keep away from sunlight



Store between 39°F - 86°F (4°C - 30°C)



Keep dry



Do not re-use

Distributed by Wondfo USA Co., Ltd.
 545 Willowbrook Centre Parkway, Unit B
 Willowbrook, IL 60527
 www.wondfousa.com
 Made in China

Rev. A1
 Rel.: 2023/01/24